Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SET
REST API REST API
Homo sapiens
SET is differentially expressed in 332 experiments: 125 organism parts: liver, heart, ... (123 more);, 267 disease states: normal, colon carcinoma, ... (265 more);, 107 cell types 405 cell lines 41 compound treatments and 80 other conditions.
Synonyms 2PP2A, IPP2A2, PHAPII
Orthologs Set (Mus musculus)   F6ZZP0_CIOIN (Ciona intestinalis)   F2Z4L4_CHICK (Gallus gallus)   F6ZZP5_CIOIN (Ciona intestinalis)   Set (Drosophila melanogaster)   set (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term protein phosphatase type 2A regulator activity, cytosol, endoplasmic reticulum, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, histone binding, protein complex, RNA metabolic process, nucleus, perinuclear region of cytoplasm, nucleoplasm, nucleocytoplasmic transport, nucleosome assembly, DNA replication, negative regulation of neuron apoptosis, mRNA metabolic process, negative regulation of histone acetylation, nucleosome disassembly, protein phosphatase inhibitor activity
InterPro Term NAP_family
UniProt Accession B2REB7, B2REB8, Q01105, Q5VXV3, Q5VXV2, A6NGV1
Search EB-eye ENSG00000119335
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, E-GEOD-8167, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
BT474
3
E-MEXP-440, E-MTAB-62, E-MTAB-37
WI38
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HepG2
2
E-GEOD-21154, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
399 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-13909, ... (47 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-3982
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
epithelial cell
1
2
E-GEOD-10797, E-MEXP-2034, E-GEOD-4483
stromal cell
1
2
E-GEOD-10797, E-GEOD-1460, E-MEXP-2034
mononuclear cell
1
E-GEOD-6053
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (69 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
prostate carcinoma
4
E-MTAB-62, E-MEXP-2034, E-GEOD-96, E-MEXP-1327
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
261 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-697, ... (30 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5824, E-TABM-782, E-TABM-868, E-GEOD-412, E-MEXP-1958, ... (12 experiments)
control
1
3
E-GEOD-3284, E-GEOD-4006, E-GEOD-995, E-GEOD-5339
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
U0126
1
E-GEOD-697
ox-LDL
1
E-GEOD-5741
chloroguine
1
E-GEOD-5418
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-18005, E-TABM-868, E-MEXP-1403, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-26, ... (39 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (9 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-TABM-43, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.458 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM